ISC-hpNSC vs OK99
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: neural stem cell therapy · full Parkinson's Disease pipeline
ISC-hpNSC
Developed by Cyto Therapeutics Pty Limited and partners
NCT02452723 · Phase 1 · completed
This was a small, open-label, single-arm safety study of a stem-cell transplant procedure, with no randomization or control group. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, related TEAEs, severe TEAEs (12 month): No serious adverse effects related to the transplanted cells occurred in any of the three cohorts; treatment was safe and well tolerated over at least two years in this 12-patient trial.
Result source: NCT02452723
OK99
Developed by Celavie Biosciences, LLC
NCT02780895 · Phase 1 · status unknown
This was an uncontrolled, open-label surgical study in only 8 patients, with no comparator group and no blinding, so it cannot show a treatment effect distinct from surgical or placebo effects; no results have been posted.
No aligned efficacy figure on record for this race.
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ISC-hpNSC | OK99 |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- ISC-hpNSC
- —Not reported
- OK99
- —Not reported
ON time without troublesome dyskinesia, change
- ISC-hpNSC
- —Not reported
- OK99
- —Not reported
UPDRS Part III, change
- ISC-hpNSC
- —Not reported
- OK99
- —Not reported
MDS-UPDRS Part II, change
- ISC-hpNSC
- —Not reported
- OK99
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ISC-hpNSC: no structured comparison results are available for Parkinson's Disease.
OK99: no structured comparison results are available for Parkinson's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ISC-hpNSC's landscape · OK99's landscape